Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) EBITDA
Merck & Co., Inc.'s EBITDA for fiscal 2025 was $27.9B, up 13.0% from $24.7B in fiscal 2024. Over the twelve months to 30 June 2026 it was $13.7B. Over the past ten years it has ranged from $6.8B (fiscal 2023) to $27.9B (fiscal 2025) — the current reading is the highest in ten years. Merck & Co., Inc. ranks 10th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $27.9B | 13.05% |
| FY2024 | $24.7B | 262.14% |
| FY2023 | $6.8B | (69.24%) |
| FY2022 | $22.2B | 35.20% |
| FY2021 | $16.4B | 81.68% |
| FY2020 | $9.0B | (19.60%) |
| FY2019 | $11.2B | (16.46%) |
| FY2018 | $13.5B | 17.23% |
| FY2017 | $11.5B | 4.59% |
| FY2016 | $11.0B | (21.20%) |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.2B | — |
| Mar 2026 | −$1.7B | — |
| Dec 2025 | $6.5B | (15.28%) |
| Sep 2025 | $7.7B | 15.54% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| JNJ Johnson & Johnson compare | $34.9B |
| NVO Novo Nordisk A/S compare | $26.5B |
| ABBV AbbVie Inc. compare | $25.6B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. compare | $16.5B |
| MRK Merck & Co., Inc. | $13.7B |
| GILD Gilead Sciences, Inc. compare | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on MRK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement